Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination

We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination.We evaluated clinical phenotypes, annualised relapse rates (ARR) prior and on immunotherapy and Expanded Disability Status Scale (EDSS), in 218 demyelinating episodes from 33 paediatric and 26 adult patients.The most common initial presentation in the cohort was optic neuritis (ON)...